Aflibercept as a VEGF Decoy Receptor

What is aflibercept's mechanism as a soluble decoy receptor that binds VEGF-A and PlGF?

Aflibercept functions as a soluble decoy receptor by binding VEGF-A and PlGF with high affinity in 1:1 complexes, preventing these ligands from activating their native VEGFR1 and VEGFR2 receptors and thereby blocking downstream angiogenic signaling pathways.

Abstract

Aflibercept functions as a soluble decoy receptor composed of the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2 fused to the Fc region of human IgG1. It binds all isoforms of human VEGF-A with subpicomolar affinity (Kd = 0.49-0.5 pM) and PlGF with low picomolar affinity (Kd = 38.9 pM for human PlGF-2), forming homogeneous 1:1 complexes with each VEGF dimer. This binding mechanism occludes both the amino acids necessary for VEGFR1/R2 binding and the heparin-binding site on VEGF165, preventing VEGF-A and PlGF from activating their native receptors. The association rate for aflibercept binding to VEGF-A is orders of magnitude faster than bevacizumab and ranibizumab, and unlike these antibody-based approaches, aflibercept also binds VEGF-B and PlGF, providing broader VEGF family inhibition.

By sequestering VEGF-A and PlGF from circulation, aflibercept suppresses phosphorylation of VEGFR1 and VEGFR2 and downstream pathways including PI3K/AKT/mTOR and ERK, resulting in reduced endothelial cell proliferation, migration, and permeability. The monomeric 1:1 complex formation distinguishes aflibercept from bevacizumab’s multimeric complexes and avoids platelet activation and increased Fcγ receptor binding. An unexpected mechanistic property is aflibercept’s glycosylation-dependent binding to galectin-1, an angiogenic factor independent of VEGF-A, representing a novel anti-angiogenic function beyond VEGF family antagonism.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200 Papers screened using: Aflibercept Mechanism Focus, Target Binding Interactions, Mechanistic Data Provision, Appropriate Methodology, Beyond Clinical Outcomes Only, Aflibercept Inclusion, Publication Type Adequacy
• n = 10 Papers included for extraction

Screening

We screened in sources based on their abstracts that met these criteria:

• Aflibercept Mechanism Focus: Does this study investigate aflibercept’s molecular mechanism of action as a decoy receptor?
• Target Binding Interactions: Does this study examine aflibercept’s binding interactions with VEGF-A and/or PlGF?
• Mechanistic Data Provision: Does this study provide mechanistic data through in vitro, in vivo, ex vivo, or clinical approaches?
• Appropriate Methodology: Does this study use biochemical, biophysical, molecular biology, or structural techniques to characterize aflibercept?
• Beyond Clinical Outcomes Only: Does this study provide mechanistic insights beyond solely reporting clinical efficacy or safety outcomes?
• Aflibercept Inclusion: Does this study include aflibercept as a primary focus or in direct comparison?
• Publication Type Adequacy: Is this study a full research article, review, or other substantial publication?

Data extraction

We asked a large language model to extract each data column below from each paper:

Binding Properties

• Affinity and Kinetics
  Aflibercept demonstrated subpicomolar affinity for all isoforms of human VEGF-A tested, with Kd values of 0.490 pM for VEGF-A165 and 0.5 pM in pharmacokinetic studies. For PlGF-2, aflibercept exhibited Kd values of 38.9 pM for human PlGF-2 and 3.32 pM for murine PlGF-2.

Structural Mechanism

• Domain Architecture
  Aflibercept functions as a soluble decoy receptor composed of the second Ig domain of human VEGFR1 and the third Ig domain of human VEGFR2, fused to the Fc region of human IgG1.

Decoy Receptor Function

• Prevention of Native Receptor Activation
  Aflibercept prevented VEGF-A and PlGF from binding to their native receptors, VEGFR1 and VEGFR2. The high-affinity binding effectively sequestered them from circulation, reducing their availability for endogenous receptors.

Downstream Signaling Effects

• Impact on Signaling Pathways
  Aflibercept suppressed phosphorylation of PI3K, AKT, and mTOR pathways.

Ligand Specificity Profile

• Binding Status
  Aflibercept binds VEGF-A, VEGF-B, and PlGF, with a high binding affinity across multiple species including human and mouse.

Mechanistic Comparison

• Differences from antibody-based approaches
  Aflibercept is a decoy receptor with broader specificity compared to antibodies like ranibizumab and bevacizumab.